Furthermore, the HER2 status of CTCs was not consistent with the HER2 status of the corresponding BC, suggesting that a subgroup of patients with BC with HER2-positive CTCs may benefit from HER2-targeted therapy. This evidence concerns the gene ERBB2 and breast cancer.